Juliana Rose Cinque, MD
Dermatology · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
- Since medical school
- 50 years
- University of Southern California Keck School of Medicine, 1976
Offices
1 location
Hospitals listed: Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cinque’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G34585 · Current
Licensed to practise in California · since 1977 · expires 2027-10-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$215,648
Medicare paid this office $215,648 for 488 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 239 | $48,146 | $107 |
| Short return visit (20+ min) | 282 | $32,447 | $76 |
| Destruction of precancer skin growth, 1 growth | 283 | $26,653 | $51 |
| Destruction of skin growth, 1-14 growths | 187 | $26,615 | $104 |
| Destruction of precancer skin growth, 2-14 growths | 205 | $13,135 | $7 |
See all 17 services
| Return visit (30+ min) | 239 | $48,146 | $107 |
| Short return visit (20+ min) | 282 | $32,447 | $76 |
| Destruction of precancer skin growth, 1 growth | 283 | $26,653 | $51 |
| Destruction of skin growth, 1-14 growths | 187 | $26,615 | $104 |
| Destruction of precancer skin growth, 2-14 growths | 205 | $13,135 | $7 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 53 | $9,299 | $126 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 45 | $6,364 | $118 |
| Destruction of precancer skin growth, 15 or more growths | 25 | $5,522 | $167 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 28 | $5,293 | $139 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 40 | $4,802 | $104 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 28 | $4,336 | $128 |
| New patient visit (45+ min) | 26 | $3,353 | $129 |
| Short return visit | 52 | $2,982 | $50 |
| Biopsy of related skin growth, first growth | 27 | $2,119 | $76 |
| New patient visit (30+ min) | 22 | $1,665 | $76 |
| Simple or single drainage of skin abscess | 11 | $1,401 | $117 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 46 | $1,183 | $24 |
Procedures Medicare counted
| Removal of skin lesions | 1037 | More than 93% of doctors who do this |
| Removal of tissue | 1-10 | None |
| Removal or shaving of skin growth | 79 | More than 83% of doctors who do this |
| Skin biopsy | 154 | More than 81% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 2,834 | 1,767 | 2,040 | 1,895 | 1,756 | 1,958 |
| Destruction of precancer skin growth, 1 growth | 606 | 413 | 485 | 525 | 534 | 519 |
| Destruction of skin growth, 1-14 growths | 249 | 164 | 210 | 249 | 294 | 255 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 52 | 61 | 87 | 79 | 82 | 74 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 29 | 24 | 44 | 39 | 30 | 54 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 36 | 27 | 29 | 30 | 40 | 46 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
488 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 15% · Women 60% · Also on Medicaid 3% · Health risk score 0.87. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 64% · Chronic kidney disease 22% · Coronary heart disease 17% · Diabetes 16% · Cancer 14% · Atrial fibrillation 14% · Depression 12% · Heart failure 9% · COPD 8% · Dementia 3% · Stroke 3%.
The office billed $400,611, Medicare allowed $295,808 and paid $215,648; for 4,319 services of 54 kinds; $1,961 of it was for drugs given in the office and $213,687 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 488 | 4,319 | 76 | 0.87 | $400,611 | $215,648 |
| 2023 | 513 | 4,099 | 75 | 0.90 | $401,174 | $207,111 |
| 2022 | 482 | 4,050 | 76 | 0.89 | $358,833 | $186,795 |
| 2021 | 409 | 3,905 | 76 | 0.94 | $323,019 | $178,615 |
| 2020 | 364 | 3,257 | 76 | 0.96 | $237,478 | $113,801 |
| 2019 | 450 | 5,118 | 75 | 0.88 | $406,752 | $173,089 |
| 2018 | 428 | 4,781 | 75 | 0.88 | $387,935 | $164,019 |
| 2017 | 438 | 5,271 | 75 | 0.97 | $442,831 | $176,355 |
| 2016 | 415 | 4,871 | 75 | 1.01 | $388,615 | $146,144 |
| 2015 | 430 | 3,842 | 75 | 0.92 | $321,567 | $124,422 |
| 2014 | 425 | 3,323 | 75 | 0.86 | $308,769 | $132,070 |
| 2013 | 384 | 2,775 | 75 | 0.82 | $262,346 | $123,566 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Return visit (30+ min) | 246 | $46,941 | $106 |
| Short return visit (20+ min) | 282 | $31,516 | $73 |
| Destruction of skin growth, 1-14 growths | 208 | $29,720 | $101 |
| Destruction of precancer skin growth, 1 growth | 289 | $25,731 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 202 | $11,458 | $7 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 63 | $9,805 | $120 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 38 | $4,448 | $111 |
| New patient visit (45+ min) | 36 | $4,411 | $123 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 30 | $4,072 | $127 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 28 | $3,758 | $125 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 27 | $3,544 | $118 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 12 | $3,443 | None |
| Destruction of precancer skin growth, 15 or more growths | 15 | $2,838 | $167 |
| Short return visit | 54 | $2,704 | $46 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 21 | $2,418 | $110 |
| New patient visit (30+ min) | 33 | $2,350 | $71 |
| Biopsy of related skin growth, first growth | 22 | $2,111 | $84 |
| Simple or single drainage of skin abscess | 15 | $1,472 | $98 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 38 | $966 | $24 |
2022: 17 services
| Return visit (30+ min) | 214 | $39,313 | $105 |
| Short return visit (20+ min) | 285 | $30,912 | $74 |
| Destruction of precancer skin growth, 1 growth | 285 | $26,088 | $50 |
| Destruction of skin growth, 1-14 growths | 192 | $25,180 | $101 |
| Destruction of precancer skin growth, 2-14 growths | 208 | $12,621 | $7 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 64 | $9,517 | $120 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 29 | $4,131 | $138 |
| New patient visit (45+ min) | 32 | $4,017 | $126 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 34 | $3,894 | $100 |
| Short return visit | 56 | $2,860 | $46 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 27 | $2,840 | $95 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $2,766 | $163 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 20 | $2,745 | $119 |
| New patient visit (30+ min) | 36 | $2,536 | $70 |
| Shaving of skin growth of body, arms, or legs, more than 2.0 cm | 13 | $1,806 | $129 |
| Simple or single drainage of skin abscess | 14 | $1,531 | $109 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 11 | $1,247 | $113 |
2021: 16 services
| Short return visit (20+ min) | 262 | $31,042 | $77 |
| Return visit (30+ min) | 160 | $28,292 | $116 |
| Destruction of precancer skin growth, 1 growth | 259 | $24,437 | $50 |
| Destruction of skin growth, 1-14 growths | 156 | $22,178 | $106 |
| Destruction of precancer skin growth, 2-14 growths | 210 | $13,424 | $7 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 63 | $11,391 | $131 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 29 | $5,817 | $149 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 38 | $5,424 | $123 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 28 | $4,589 | $135 |
| New patient visit (45+ min) | 30 | $3,905 | $130 |
| Destruction of precancer skin growth, 15 or more growths | 16 | $3,823 | $159 |
| Short return visit | 60 | $3,425 | $47 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 26 | $2,800 | $97 |
| New patient visit (30+ min) | 30 | $2,291 | $76 |
| Shaving of skin growth of body, arms, or legs, more than 2.0 cm | 15 | $2,167 | $135 |
| Simple or single drainage of skin abscess | 15 | $1,408 | $94 |
2020: 13 services
| Short return visit (20+ min) | 297 | $29,097 | $59 |
| Destruction of precancer skin growth, 1 growth | 240 | $19,096 | $46 |
| Destruction of skin growth, 1-14 growths | 127 | $15,428 | $94 |
| Destruction of precancer skin growth, 2-14 growths | 190 | $10,439 | $6 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 48 | $7,601 | $125 |
| Short return visit | 79 | $3,423 | $37 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 23 | $3,375 | $130 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 22 | $3,073 | $128 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 16 | $3,014 | $144 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 24 | $2,895 | $107 |
| Destruction of skin growth, 15 or more growths | 11 | $1,528 | $127 |
| Simple or single drainage of skin abscess | 12 | $1,145 | $88 |
| New patient visit (15+ min) | 13 | $754 | $58 |
2019: 18 services
| Short return visit (20+ min) | 363 | $49,048 | $62 |
| Destruction of precancer skin growth, 1 growth | 305 | $28,775 | $47 |
| Destruction of skin growth, 1-14 growths | 189 | $24,883 | $100 |
| Destruction of precancer skin growth, 2-14 growths | 248 | $15,082 | $5 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 48 | $6,518 | $125 |
| Destruction of precancer skin growth, 15 or more growths | 35 | $6,470 | $135 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 27 | $4,966 | $146 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 33 | $3,217 | $89 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 28 | $3,125 | $108 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 21 | $3,035 | $126 |
| Short return visit | 77 | $2,967 | $34 |
| New patient visit (30+ min) | 36 | $2,766 | $77 |
| Shaving of skin growth of body, arms, or legs, more than 2.0 cm | 17 | $2,658 | $140 |
| Destruction of skin growth, 15 or more growths | 20 | $2,563 | $116 |
| New patient visit (15+ min) | 35 | $2,237 | $64 |
| Return visit (30+ min) | 11 | $1,361 | $91 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 11 | $1,121 | $93 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $637 | $22 |
2018: 20 services
| Short return visit (20+ min) | 361 | $46,172 | $60 |
| Destruction of skin growth, 1-14 growths | 183 | $25,590 | $100 |
| Destruction of precancer skin growth, 1 growth | 266 | $24,275 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 230 | $12,623 | $5 |
| Destruction of precancer skin growth, 15 or more growths | 41 | $8,048 | $136 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 37 | $5,300 | $129 |
| Biopsy of single growth of skin and/or tissue | 42 | $3,553 | $79 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 35 | $3,390 | $87 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 21 | $3,306 | $150 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 23 | $3,197 | $128 |
| Short return visit | 72 | $3,095 | $40 |
| New patient visit (30+ min) | 33 | $2,868 | $87 |
| Destruction of skin growth, 15 or more growths | 14 | $2,330 | $129 |
| New patient visit (15+ min) | 39 | $2,297 | $59 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 15 | $1,733 | $116 |
| Shaving of skin growth of body, arms, or legs, more than 2.0 cm | 11 | $1,600 | $145 |
| Return visit (30+ min) | 16 | $1,250 | $78 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 11 | $1,126 | $102 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $362 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $29 | None |
2017: 19 services
| Short return visit (20+ min) | 361 | $48,231 | $57 |
| Destruction of precancer skin growth, 1 growth | 276 | $24,708 | $45 |
| Destruction of skin growth, 1-14 growths | 146 | $17,930 | $96 |
| Destruction of precancer skin growth, 2-14 growths | 250 | $14,186 | $5 |
| Destruction of precancer skin growth, 15 or more growths | 48 | $9,565 | $137 |
| Biopsy of single growth of skin and/or tissue | 93 | $8,411 | $78 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 40 | $5,837 | $119 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 32 | $4,400 | $129 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 45 | $4,255 | $82 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 27 | $3,801 | $123 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 13 | $3,455 | None |
| New patient visit (15+ min) | 56 | $3,150 | $56 |
| Short return visit | 71 | $2,875 | $35 |
| Destruction of skin growth, 15 or more growths | 18 | $2,566 | $117 |
| New patient visit (30+ min) | 30 | $2,462 | $82 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 19 | $2,079 | $104 |
| Application of light to destroy precancer skin growth | 13 | $1,764 | $136 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 13 | $1,144 | $88 |
| Biopsy of each additional growth of skin and/or tissue | 14 | $467 | $29 |
2016: 18 services
| Short return visit (20+ min) | 348 | $41,717 | $56 |
| Destruction of precancer skin growth, 1 growth | 257 | $21,645 | $42 |
| Destruction of skin growth, 1-14 growths | 145 | $17,374 | $93 |
| Destruction of precancer skin growth, 2-14 growths | 231 | $13,088 | $5 |
| Destruction of precancer skin growth, 15 or more growths | 47 | $8,272 | $129 |
| Biopsy of single growth of skin and/or tissue | 75 | $6,008 | $70 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 34 | $4,674 | $117 |
| Short return visit | 97 | $3,497 | $33 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 31 | $3,302 | $92 |
| Destruction of skin growth, 15 or more growths | 23 | $3,121 | $111 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 37 | $2,929 | $71 |
| New patient visit (15+ min) | 49 | $2,735 | $56 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 15 | $2,385 | $133 |
| New patient visit (30+ min) | 28 | $2,092 | $75 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 14 | $1,925 | $113 |
| Simple or single drainage of skin abscess | 16 | $1,464 | $92 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 12 | $1,316 | $94 |
| Biopsy of ear | 11 | $791 | $66 |
2015: 16 services
| Short return visit (20+ min) | 319 | $32,072 | $56 |
| Destruction of precancer skin growth, 1 growth | 270 | $21,609 | $44 |
| Biopsy of single growth of skin and/or tissue | 111 | $11,157 | $80 |
| Destruction of skin growth, 1-14 growths | 89 | $9,996 | $98 |
| Destruction of precancer skin growth, 2-14 growths | 221 | $9,288 | $5 |
| Short return visit | 109 | $4,922 | $36 |
| Destruction of precancer skin growth, 15 or more growths | 26 | $4,582 | $135 |
| New patient visit (15+ min) | 56 | $3,027 | $54 |
| New patient visit (30+ min) | 35 | $2,825 | $81 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 18 | $2,451 | $129 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 22 | $2,284 | $104 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 24 | $2,245 | $86 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 17 | $2,187 | $122 |
| Return visit (30+ min) | 19 | $1,093 | $52 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 13 | $1,084 | $83 |
| Biopsy of each additional growth of skin and/or tissue | 26 | $899 | $28 |
2014: 18 services
| Destruction of precancer skin growth, 1 growth | 220 | $22,978 | $53 |
| Short return visit (20+ min) | 233 | $22,849 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 177 | $13,955 | $9 |
| Return visit (30+ min) | 141 | $12,922 | $82 |
| Biopsy of single growth of skin and/or tissue | 87 | $9,061 | $79 |
| Destruction of skin growth, 1-14 growths | 78 | $8,187 | $94 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 49 | $5,078 | $83 |
| Short return visit | 102 | $4,073 | $33 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 31 | $3,921 | $119 |
| Destruction of precancer skin growth, 15 or more growths | 19 | $3,768 | $126 |
| New patient visit (30+ min) | 42 | $3,180 | $76 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 22 | $2,956 | $118 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 27 | $2,834 | $94 |
| New patient visit (15+ min) | 55 | $2,702 | $49 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $2,154 | $144 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 20 | $1,927 | $92 |
| Biopsy of ear | 16 | $1,326 | $78 |
| Biopsy of each additional growth of skin and/or tissue | 17 | $691 | $29 |
2013: 17 services
| Destruction of precancer skin growth, 1 growth | 198 | $22,722 | $62 |
| Short return visit (20+ min) | 208 | $19,970 | $58 |
| Return visit (30+ min) | 135 | $11,778 | $81 |
| Biopsy of single growth of skin and/or tissue | 108 | $10,717 | $82 |
| Destruction of precancer skin growth, 2-14 growths | 155 | $7,270 | $6 |
| Destruction of skin growth, 1-14 growths | 53 | $5,632 | $99 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 14 | $4,380 | $274 |
| Short return visit | 94 | $3,875 | $34 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 29 | $2,902 | $94 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 30 | $2,764 | $89 |
| Destruction of precancer skin growth, 15 or more growths | 17 | $2,701 | $142 |
| New patient visit (30+ min) | 30 | $2,540 | $85 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 26 | $2,376 | $91 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 16 | $2,131 | $125 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 12 | $1,976 | $132 |
| New patient visit (15+ min) | 39 | $1,972 | $51 |
| Biopsy of each additional growth of skin and/or tissue | 14 | $525 | $29 |
Drugs they prescribed that Part D paid
$175,458
Pharmacies billed $175,458 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 628) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
611 generic and 17 brand-name prescriptions · $175,458 in drug cost · 94 antibiotic prescriptions to 37 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 12 | $160,888 | $13,407 |
| Betamethasone Dipropionate | 70 | $2,705 | $39 |
| Fluorouracil | 26 | $1,627 | $63 |
| Clobetasol Propionate | 24 | $1,612 | $67 |
| Minocycline | 28 | $813 | $29 |
See all 17 drugs
| Humira(Cf) | 12 | $160,888 | $13,407 |
| Betamethasone Dipropionate | 70 | $2,705 | $39 |
| Fluorouracil | 26 | $1,627 | $63 |
| Clobetasol Propionate | 24 | $1,612 | $67 |
| Minocycline | 28 | $813 | $29 |
| Doxycycline Hyclate | 38 | $549 | $14 |
| Clindamycin Phosphate | 17 | $467 | $27 |
| Ketoconazole | 46 | $444 | $10 |
| Mometasone Furoate | 26 | $350 | $13 |
| Triamcinolone Acetonide | 86 | $341 | $4 |
| Imiquimod | 12 | $277 | $23 |
| Betamethasone Diprop Augmented | 17 | $247 | $15 |
| Mupirocin | 40 | $243 | $6 |
| Minoxidil | 32 | $120 | $4 |
| Hydrocortisone | 22 | $103 | $5 |
| Clindamycin | 11 | $83 | $8 |
| Prednisone | 16 | $59 | $4 |
Year by year
| 2024 | 628 | 236 | 0% (0) | 3% | $175,458 |
| 2023 | 634 | 244 | 0% (0) | 4% | $67,101 |
| 2022 | 511 | 211 | 0% (0) | 4% | $31,368 |
| 2021 | 329 | 145 | 0% (0) | 9% | $24,315 |
| 2020 | 275 | 115 | 0% (0) | 18% | $93,885 |
| 2019 | 412 | 176 | 0% (0) | 19% | $121,330 |
| 2018 | 342 | 141 | None | 12% | $71,247 |
| 2017 | 336 | 148 | 0% (0) | 12% | $65,291 |
| 2016 | 358 | 150 | None | None | $52,942 |
| 2015 | 327 | 142 | None | 17% | $46,928 |
| 2014 | 277 | 128 | None | 16% | $40,222 |
| 2013 | 299 | 113 | None | 11% | $24,220 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Betamethasone Dipropionate | 76 | $3,368 | $44 |
| Metronidazole | 27 | $1,752 | $65 |
| Doxycycline Hyclate | 36 | $1,638 | $45 |
| Fluorouracil | 20 | $1,637 | $82 |
| Ketoconazole | 62 | $1,025 | $17 |
| Clobetasol Propionate | 13 | $865 | $67 |
| Minocycline | 35 | $753 | $22 |
| Clindamycin Phosphate | 16 | $620 | $39 |
| Triamcinolone Acetonide | 78 | $574 | $7 |
| Betamethasone Diprop Augmented | 14 | $517 | $37 |
| Mometasone Furoate | 22 | $398 | $18 |
| Mupirocin | 37 | $258 | $7 |
| Minoxidil | 20 | $224 | $11 |
| Hydrocortisone | 29 | $220 | $8 |
| Prednisone | 26 | $138 | $5 |
2022: 15 drugs
| Fluorouracil | 18 | $3,034 | $169 |
| Betamethasone Dipropionate | 50 | $2,505 | $50 |
| Metronidazole | 19 | $1,244 | $65 |
| Doxycycline Hyclate | 39 | $1,081 | $28 |
| Minocycline | 33 | $832 | $25 |
| Clindamycin Phosphate | 14 | $827 | $59 |
| Ketoconazole | 41 | $688 | $17 |
| Mometasone Furoate | 33 | $588 | $18 |
| Clobetasol Propionate | 12 | $564 | $47 |
| Betamethasone Diprop Augmented | 21 | $466 | $22 |
| Alclometasone Dipropionate | 13 | $384 | $30 |
| Mupirocin | 35 | $318 | $9 |
| Triamcinolone Acetonide | 53 | $305 | $6 |
| Hydrocortisone | 23 | $175 | $8 |
| Prednisone | 13 | $62 | $5 |
2021: 11 drugs
| Metronidazole | 25 | $1,684 | $67 |
| Betamethasone Dipropionate | 28 | $1,521 | $54 |
| Ketoconazole | 31 | $760 | $25 |
| Doxycycline Hyclate | 31 | $734 | $24 |
| Clindamycin Phosphate | 11 | $632 | $57 |
| Minocycline | 19 | $540 | $28 |
| Alclometasone Dipropionate | 16 | $533 | $33 |
| Mometasone Furoate | 20 | $342 | $17 |
| Mupirocin | 23 | $215 | $9 |
| Triamcinolone Acetonide | 31 | $189 | $6 |
| Hydrocortisone | 18 | $82 | $5 |
2020: 8 drugs
| Betamethasone Dipropionate | 37 | $2,116 | $57 |
| Fluorouracil | 12 | $1,462 | $122 |
| Metronidazole | 13 | $1,078 | $83 |
| Fluocinonide | 15 | $859 | $57 |
| Doxycycline Hyclate | 18 | $669 | $37 |
| Ketoconazole | 22 | $384 | $17 |
| Mometasone Furoate | 17 | $278 | $16 |
| Triamcinolone Acetonide | 21 | $163 | $8 |
2019: 14 drugs
| Humira | 11 | $56,018 | $5,093 |
| Fluorouracil | 29 | $4,838 | $167 |
| Betamethasone Dipropionate | 47 | $2,463 | $52 |
| Metronidazole | 19 | $2,081 | $110 |
| Betamethasone Diprop Augmented | 31 | $1,330 | $43 |
| Fluocinonide | 13 | $780 | $60 |
| Doxycycline Hyclate | 23 | $767 | $33 |
| Alclometasone Dipropionate | 21 | $658 | $31 |
| Triamcinolone Acetonide | 44 | $481 | $11 |
| Mometasone Furoate | 15 | $350 | $23 |
| Ketoconazole | 20 | $341 | $17 |
| Mupirocin | 22 | $187 | $8 |
| Prednisone | 14 | $108 | $8 |
| Hydrocortisone | 14 | $62 | $4 |
2018: 14 drugs
| Humira | 11 | $56,915 | $5,174 |
| Minocycline | 20 | $1,593 | $80 |
| Betamethasone Diprop Augmented | 30 | $1,332 | $44 |
| Fluorouracil | 11 | $1,203 | $109 |
| Betamethasone Dipropionate | 18 | $881 | $49 |
| Doxycycline Hyclate | 18 | $837 | $47 |
| Fluocinonide | 11 | $591 | $54 |
| Alclometasone Dipropionate | 12 | $464 | $39 |
| Ketoconazole | 15 | $396 | $26 |
| Mometasone Furoate | 15 | $272 | $18 |
| Triamcinolone Acetonide | 34 | $240 | $7 |
| Spironolactone | 15 | $215 | $14 |
| Mupirocin | 18 | $174 | $10 |
| Hydrocortisone | 14 | $73 | $5 |
2017: 13 drugs
| Fluorouracil | 12 | $1,572 | $131 |
| Betamethasone Dipropionate | 31 | $1,508 | $49 |
| Clobetasol Propionate | 11 | $1,206 | $110 |
| Clindamycin Phosphate | 11 | $578 | $53 |
| Alclometasone Dipropionate | 16 | $565 | $35 |
| Imiquimod | 11 | $517 | $47 |
| Mometasone Furoate | 27 | $381 | $14 |
| Doxycycline Hyclate | 11 | $344 | $31 |
| Ketoconazole | 16 | $309 | $19 |
| Triamcinolone Acetonide | 29 | $285 | $10 |
| Mupirocin | 21 | $174 | $8 |
| Hydrocortisone | 13 | $105 | $8 |
| Cephalexin | 16 | $82 | $5 |
2016: 12 drugs
| Clobetasol Propionate | 15 | $1,918 | $128 |
| Desoximetasone | 33 | $1,759 | $53 |
| Fluocinonide | 22 | $1,375 | $62 |
| Metronidazole | 12 | $1,139 | $95 |
| Betamethasone Dipropionate | 21 | $1,105 | $53 |
| Alclometasone Dipropionate | 21 | $787 | $37 |
| Clindamycin Phosphate | 12 | $724 | $60 |
| Ketoconazole | 15 | $582 | $39 |
| Doxycycline Hyclate | 13 | $520 | $40 |
| Triamcinolone Acetonide | 32 | $224 | $7 |
| Mupirocin | 24 | $211 | $9 |
| Cephalexin | 19 | $111 | $6 |
2015: 9 drugs
| Desoximetasone | 35 | $3,747 | $107 |
| Clobetasol Propionate | 11 | $1,546 | $141 |
| Doxycycline Hyclate | 19 | $864 | $45 |
| Alclometasone Dipropionate | 19 | $728 | $38 |
| Betamethasone Dipropionate | 11 | $536 | $49 |
| Triamcinolone Acetonide | 30 | $377 | $13 |
| Ketoconazole | 16 | $302 | $19 |
| Cephalexin | 17 | $76 | $4 |
| Prednisone | 13 | $48 | $4 |
2014: 6 drugs
| Desoximetasone | 26 | $3,537 | $136 |
| Fluocinonide | 16 | $1,146 | $72 |
| Clindamycin Phosphate | 15 | $1,123 | $75 |
| Alclometasone Dipropionate | 22 | $1,112 | $51 |
| Triamcinolone Acetonide | 12 | $159 | $13 |
| Cephalexin | 14 | $82 | $6 |
2013: 9 drugs
| Diflorasone Diacetate | 22 | $4,346 | $198 |
| Desoximetasone | 24 | $3,030 | $126 |
| Clobetasol Propionate | 15 | $1,067 | $71 |
| Alclometasone Dipropionate | 16 | $676 | $42 |
| Hydrocortisone Butyrate | 12 | $498 | $42 |
| Mometasone Furoate | 15 | $307 | $20 |
| Doxepin | 12 | $116 | $10 |
| Minocycline | 11 | $98 | $9 |
| Cephalexin | 14 | $90 | $6 |
Money from drug and device companies
$822 in 2025
| 2025 | 12 | 31 | None | $822 |
| 2024 | 10 | 31 | None | $675 |
| 2023 | 10 | 25 | None | $783 |
| 2022 | 3 | 7 | None | $303 |
| 2021 | 2 | 2 | None | $35 |
| 2019 | 1 | 1 | None | $86 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $164 | 5 payments
|
| Abbvie | Skyrizi | $138 | 7 payments
|
| Lilly USA | Taltz | $121 | 4 payments
|
| Galderma Laboratories L.P. | Nemluvio | $89 | 3 payments
|
| Arcutis Biotherapeutics | Zoryve | $61 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $45 | 2 payments
|
See all 31 published payments
| Arcutis Biotherapeutics | Meals · 2025-12-12 | Zoryve | $22 |
| Novartis Pharmaceuticals | Meals · 2025-12-08 | Rhapsido | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-12-06 | Dupixent | $14 |
| Janssen Biotech | Meals · 2025-12-01 | Tremfya | $37 |
| Ucb | Meals · 2025-11-25 | Bimzelx | $41 |
| LEO Pharma | Meals · 2025-11-19 | Anzupgo | $28 |
| Galderma Laboratories L.P. | Meals · 2025-11-13 | Nemluvio | $27 |
| Abbvie | Meals · 2025-11-10 | Skyrizi | $13 |
| Arcutis Biotherapeutics | Meals · 2025-11-10 | Zoryve | $16 |
| Abbvie | Meals · 2025-11-04 | Skyrizi | $24 |
| Abbvie | Meals · 2025-10-29 | Skyrizi | $31 |
| Galderma Laboratories L.P. | Meals · 2025-10-28 | Nemluvio | $31 |
| Incyte | Meals · 2025-10-07 | Opzelura | $29 |
| Janssen Biotech | Meals · 2025-09-30 | Tremfya | $33 |
| Organon | Meals · 2025-09-22 | Vtama | $33 |
| Lilly USA | Meals · 2025-09-17 | Taltz | $30 |
| Abbvie | Meals · 2025-09-10 | Botox | $28 |
| Abbvie | Meals · 2025-09-10 | Botox | $4 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $14 |
| Abbvie | Meals · 2025-09-04 | Skyrizi | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-08-21 | Dupixent | $31 |
| Lilly USA | Meals · 2025-08-06 | Taltz | $30 |
| Janssen Biotech | Meals · 2025-07-21 | Tremfya | $40 |
| Abbvie | Meals · 2025-05-15 | Skyrizi | $13 |
| Lilly USA | Meals · 2025-05-02 | Taltz | $27 |
| Galderma Laboratories L.P. | Meals · 2025-03-26 | Nemluvio | $30 |
| Arcutis Biotherapeutics | Meals · 2025-03-17 | Zoryve | $23 |
| Pfizer | Meals · 2025-03-12 | Cibinqo | $27 |
| Organon | Meals · 2025-03-03 | Vtama | $12 |
| Janssen Biotech | Meals · 2025-02-21 | Tremfya | $40 |
| Lilly USA | Meals · 2025-02-12 | Taltz | $34 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $675
| Janssen Biotech | Tremfya | $181 | 6 payments
|
| Abbvie | Skyrizi | $155 | 10 payments
|
| Regeneron Healthcare Solutions | Dupixent | $72 | 3 payments
|
| Pfizer | Cibinqo | $52 | 3 payments
|
| Lilly USA | Taltz | $51 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $49 | 2 payments
|
| Dermavant Sciences | Vtama | $47 | 2 payments
|
| Biofrontera | Ameluz | $23 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $23 | 1 payment
|
| Phadia US | Immunocap | $22 | 1 payment
|
2023: $783
| Janssen Biotech | Tremfya | $176 | 5 payments
|
| Lilly USA | Olumiant | $124 | 1 payment
|
| Pfizer | Eucrisa | $101 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $95 | 3 payments
|
| Sun Pharmaceutical Industries | Winlevi | $64 | 2 payments
|
| Incyte | Opzelura | $55 | 2 payments
|
| Genzyme | Dupixent | $52 | 3 payments
|
| AbbVie | Skyrizi | $52 | 2 payments
|
| Dermavant Sciences | Vtama | $43 | 2 payments
|
| STRATA Skin Sciences | Xtrac | $20 | 1 payment
|
2022: $303
| Regeneron Healthcare Solutions | Dupixent | $136 | 4 payments
|
| Allergan | Botox | $130 | 1 payment
|
| Janssen Biotech | Remicade | $36 | 2 payments
|
2021: $35
| Janssen Biotech | Remicade | $23 | 1 payment
|
| Genzyme | None | $11 | 1 payment
|
2019: $86
| Stemline Therapeutics | Elzonris | $86 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 88.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1083643084
- Licence
- CA G34585California G34585: Current · expires 2027-10-31
- Trained
- University of Southern California Keck School of Medicine, 1976 · 50 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 1789 Barcelona St, Livermore, CA, 94550
- NPI first listed
- 2006-07-02
- NPI last updated
- 2013-03-26
This is when the NPI record was last certified, not a medical board exam.